Press Release



Shionogi Announces Corporate Reorganization and Personnel Reassignment

OSAKA, **Japan**, **February 24**, **2021** - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that Shionogi will implement the following corporate reorganization and personnel reassignment as of April 1, 2021.

1. Corporate Reorganization (see attached organization chart)

- (1) Reorganization of the Global Development Division

 The Regulatory Affairs Supervisor will be progressively dissolved, and the affiliated organization will be directly under the Global Development Division.
- (2) New establishment of the Vaccine Business Department
 The Vaccine Business Department will be newly established under the Integrated Disease
 Care Division as an organization to promptly launch the vaccine business and prepare for
 the supply and distribution of vaccines.

2. Personnel Reassignment (Effective; April 1, 2021)

New Position	Name	Present Position				
Integrated Disease Care Division						
Vice president, Vaccine Business Department	Norio Tamura	Vice president, Regulatory Affairs Supervisor				
UMN Pharma Inc.						
Chairman	Fumihisa Nakata	President				
President	Kazufumi Katayama	UMN Pharma Inc.				

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and

Press Release



changes of laws and regulations. Also, for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

For Further Information, Contact:

Corporate Communications Department Shionogi & Co., Ltd.

Telephone: +81-6-6209-7885

				Corporate Executive Meeting
The Annual Connel Marking of Charles			Board of Directors	<u> </u>
The Annual General Meeting of Shareholders			Board of Directors	Constitution Constitution
			Chief Executive Officer and Representative Director	Compliance Committee
	Board of	Auditors		
G				
Pharmaceutical Research Division			Research Planning Department	
			Laboratory for Drug Discovery and Disease Research Laboratory for Medicinal Chemistry Research	
			Laboratory for Drug Discovery and Development	
			Laboratory for Advanced Medicine Research	
			Laboratory for Innovative Therapy Research	
			Biomarker R&D Department	
Drug Development and Regulatory Science Division				Biostatistics Center
Drug Development and Requireory Science Division			Project Management Department	biostatistics certici
			Clinical Research Department	
			Medical Science Department	
			Government Affairs Department	
			Regulatory Affairs Department	
			Pharmacovigilance Department	
CMC R&D Division				CMC Planning Office
CIVIC NOD DIVISION			API R&D Laboratory	Civic Flaming Office
			Formulation R&D Laboratory	
			Analytical R&D Laboratory	
			Analytical R&D Laboratory	
Pharmaceutical Commercial Division				Specialty Product Office
			Sales Planning Department	
			Pharmaceutical Promotion Department - Region 1	
			Pharmaceutical Promotion Department - Region 2	
			Pharmaceutical Promotion Department - Region 3	
			Pharmaceutical Promotion Department - Region 4	
			Pharmaceutical Promotion Department - Region 5	
			Pharmaceutical Promotion Department - Region 6	
			Pharmaceutical Promotion Department - Region 7	
			Distribution Management Department	
Integrated Disease Care Division			New Product Planning Department	
			Disease Care Strategy Department	
			Medical Affairs Department	Drug Information Center
			Corporate Social Responsibility Department	Office for Children's Bright Future
			Corporate Social Responsibility Department	Office for Stewardship to Proper Use of Medicir
				Data Science Office
			Vaccine Business Department	Data Science Since
			Corporate Quality Accurance Supervisor	Promotional Compliance Office
	· <u></u>		Corporate Quality Assurance Supervisor (General Marketing Compliance Officer)	Promotional Compliance Office
			Quality Assurance Department	
			Quality Assurance Department	
Global Business Division			Global Business Department	
			Business Development Department	
Corporate Strategy Division			Corporate Planning Department	Sustainability Management Office
			Finance & Accounting Department	
			Corporate Communications Department	
			Corporate Secretariat	
			Global Supply Chain Strategy Department	
			Digital Intelligence Department	
			Intellectual Property Department	
Administration Division			Human Resources Department	
Administration Division			General Administration Department	
				\rightarrow
			Legal Affairs Department Internal Control Department	
			ппетта сопиот рерагители	
			Tokyo Branch Office	